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Intranasal acellular pertussis vaccine provides mucosal
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William T. Witt1,2, Melinda E. Varney1,2, Mariette Barbier1,2 and F. Heath Damron1,2*
Current acellular pertussis vaccines fall short of optimal protection against the human respiratory pathogen Bordetella pertussis
resulting in increased incidence of a previously controlled vaccine- preventable disease. Natural infection is known to induce a
protective mucosal immunity. Therefore, in this study, we aimed to use acellular pertussis vaccines to recapitulate these mucosal
immune responses. We utilized a murine immunization and challenge model to characterize the efficacy of intranasal immunization
(IN) with DTaP vaccine or DTaP vaccine supplemented with curdlan, a known Th1/Th17 promoting adjuvant. Protection from IN
delivered DTaP was compared to protection mediated by intraperitoneal injection of DTaP and whole-cell pertussis vaccines. We
tracked fluorescently labeled DTaP after immunization and detected that DTaP localized preferentially in the lungs while DTaP with
curdlan was predominantly in the nasal turbinates. IN immunization with DTaP, with or without curdlan adjuvant, resulted in anti-B.
pertussis and anti-pertussis toxin IgG titers at the same level as intraperitoneally administered DTaP. IN immunization was able to
protect against B. pertussis challenge and we observed decreased pulmonary pro-inflammatory cytokines, neutrophil infiltrates in
the lung, and bacterial burden in the upper and lower respiratory tract at day 3 post challenge. Furthermore, IN immunization with
DTaP triggered mucosal immune responses such as production of B. pertussis-specific IgA, and increased IL-17A. Together, the
induction of a mucosal immune response and humoral antibody-mediated protection associated with an IN administered DTaP and
curdlan adjuvant warrant further exploration as a pertussis vaccine candidate formulation.
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INTRODUCTION
Pertussis is a human upper respiratory disease, primarily caused by
the Gram-negative pathogen Bordetella pertussis. The disease is
most severe in unvaccinated infants, where it manifests as fits of
paroxysmal coughs followed by the classical whoop as air re-
enters the respiratory system, leading to the more commonly
known name: whooping cough.1 Additional complications include
vomiting, increased mucus production, and apneic episodes. In
severe cases, these symptoms can lead to elevated leukocytosis,
pulmonary hypertension, hypoxia, and in some cases death.1–3
Furthermore there is speculation that pertussis may enhance
development of neurodegenerative diseases later in life.4
In the pre-vaccine era, pertussis was responsible for 200,000
deaths annually in the United States.5 Widespread use of diphtheria
tetanus whole-cell pertussis (DTP; wP) vaccines controlled the
incidence of pertussis.6 However, adverse side effects associated
with wP immunization1 led to the development of an acellular
pertussis vaccine (DTaP; aP) that was introduced into the schedule
in 1996. In the United States the number of pertussis cases has
been increasing since the 1990s, despite high vaccine coverage.7
Additionally, increasing numbers of cases have been documented
in older children, adolescents, and adults.8 The increase in incidence
of pertussis cases suggests that current aP vaccines do not offer
complete protection from B. pertussis infection. However, they do
prevent fatal cases of pertussis as aP immunized individuals have
low death rates.8 Multiple hypotheses have been proposed
explaining the resurgence of pertussis cases including: (1) waning
of protective immunity from DTaP/Tdap,9–11 (2) vaccine driven
evolution of B. pertussis strains,12 (3) the possibility of increased
transmission through asymptomatic carriers,13 and (4) increased
surveillance and more accurate diagnoses technology.
Vaccine-induced protection in aP immunized individuals has
been associated with a robust antigen-specific IgG response to the
components of the aP vaccines.14–17 Likewise, wP immunization
also resulted in antigen-specific IgG responses; with the addition
of a shift to a more diverse T cell response, inducing cell-mediated
immunity.18 In the murine model, immunization through intra-
muscular (IM) and intraperitoneal (IP) administration has been well
characterized demonstrating a Th1/Th17 response from wP
immunized mice, and a Th2 with weak Th17 mediated response
in aP immunized mice following B. pertussis challenge.19 However,
these immunizations fail to induce the mucosal immune
responses elicited from natural infection. In murine challenge
models recent studies have revealed that protection correlates
with tissue resident memory T (TRM) cells in the lung and nasal
cavity of convalescent mice, that produce interleukin-17 (IL-17)
and interferon-gamma (IFN-γ), although TRM activity in pertussis is
yet to be studied in humans.20 TRM cells have been shown to
persist in the respiratory tissue and expand upon re-challenge of a
convalescent mouse with B. pertussis, as well as decrease bacterial
burden upon adoptive transfer to naive mice.21 More recently the
1Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA. 2Vaccine Development center at West Virginia University Health
Sciences Center West Virginia University, Morgantown, WV, USA. 3West Virginia University School of Medicine, Morgantown, WV, USA. 4Instituto de Biotecnología y Biología
Molecular (IBBM)-CCT-CONICET-La Plata, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina.
*email: fdamron@hsc.wvu.edu
www.nature.com/npjvaccines













expansion of this population has been observed following
immunization by wP, a live-attenuated wP vaccine, an outer
membrane vesicle vaccine, and intranasal administration of an aP
vaccine with TLR9 and stimulator of interferon genes (STING)
agonists.22–25 The study of this population has renewed interest in
the induction of a mucosal immune response capable of
decreasing bacterial burden at the site of infection.
The induction of a mucosal immune response to B. pertussis is
associated with the production of secretory IgA antibodies (sIgA)
in the nasal cavity. In humans previously infected with B. pertussis,
IgA antibodies have been isolated from nasal secretions.26 B.
pertussis-specific IgA antibodies isolated from convalescent
patients have been shown to inhibit adherence of B. pertussis to
respiratory epithelial cells in vitro,27 suggesting a protective role of
IgA antibodies in mucosal immunity. Initial studies using IgA-
deficient mice did not show strong support for a critical role in
bacterial clearance of the respiratory tract.28 However, work with a
live-attenuated IN pertussis vaccine (BPZE1) recently demon-
strated protective role of sIgA antibodies in the respiratory tract.24
DTaP vaccine does not contain a strong pro-inflammatory
adjuvant such as endotoxin of wP vaccine or BPZE1. We aimed to
investigate IN DTaP immunization alone or with an additional pro-
inflammatory adjuvant. We formulated vaccines containing the
adjuvant curdlan, a 1,3 β-glucan, derived from Alcaligenes faecalis.
This polysaccharide has immunostimulatory properties and forms
a “sticky” gel at a neutral pH.29 Importantly, curdlan has been
shown to bind to dendritic cells through the ligand Dectin-1,
thereby inducing expression of NF-κB leading to a Th1/Th17
mediated immune response as well as production of antigen-
specific respiratory IgA antibodies and serum IgG antibodies.30–33
Our objective was to determine whether IN DTaP immunization
would induce a protective immune response in a murine model.
We observed that the gel properties of curdlan facilitated DTaP
localization in the upper respiratory tract. We determined a
significant reduction in bacterial burden following administration
of intranasally administered DTaP vaccines. We measured high
serum and respiratory antibody responses produced, following
intranasal administration of DTaP with and without curdlan. This
study suggests mucosal vaccination with acellular vaccine may be
a strategy for decreasing incidence of pertussis.
RESULTS
Acellular pertussis vaccine was retained in the upper and lower
respiratory tract when administered by intranasal administration
Pertussis toxin (PT) is an essential virulence factor, responsible for
multiple factors in the pathogenesis of B. pertussis. PT facilitates
infection by aiding in adherence to ciliated airway epithelial cells
and through disruption of host innate immune cell recruitment to
the site of infection.34–36 In numerous studies it has been
demonstrated that neutralization of PT alone ablates symptoms
of the disease.37–40 Therefore, we proposed that neutralization of
PT at the site of infection could inhibit the systemic long-range
activity of PT before colonization of the respiratory tract. We
hypothesized that intranasal immunization would prime a
protective systemic and mucosal immune response. Furthermore,
the gel-like properties of curdlan may have a beneficial role in
increasing antigen uptake. To determine if use of curdlan would
increase vaccine retention in the respiratory system, we IN
vaccinated CD-1 mice with commercially available DTaP (IN-aP),
DTaP with curdlan (IN-caP), or PBS (mock vaccinated) and tracked
the vaccine up to 48 h after vaccination (Fig. 1a). To visualize
vaccine presence in the respiratory system we labeled DTaP
vaccine particles with a fluorophore (Fig. 1b). We measured the
size of the labeled particles and determined that size was similar
to what has been previously reported, and labeled particles were
on average were 1.52 ± 0.76 µm. These findings are comparable to
previous work which found that 90% of DTaP particles were
between 1–3 µm.41 Using in vivo animal imaging, we observed
fluorescently labeled DTaP particles in the nasal cavity at 6, 12, and
24 h post-vaccination (Fig. 1c). At 12 h post-vaccination, we
detected significantly higher levels of fluorescence in IN-caP
vaccinated mice compared to IN-aP mice (Fig. 1d), suggesting
more DTaP particles were retained in the nasal cavity. This method
resulted in the quantification of total particles in nasal cavity. To
quantify DTaP particles that were bound to innate immune cells
we utilized flow cytometry. Single-cell suspensions were prepared
from homogenized lung tissue and antigen presenting cells (APCs)
bound to DTaP were quantified as live, single cells positive for
CD11b+DTaP+ (Fig. 1e). We observed a significant increase in
CD11b+ cells that were bound to or contained DTaP particles in
IN-aP mice compared to IN-caP (Fig. 1f). Together, these data
suggest a higher deposition of DTaP in the lung with IN-aP when
compared to IN-caP. Conversely, in the nasal cavity we measured
higher levels of DTaP when mice were vaccinated with IN-caP,
compared to IN-aP. These findings suggest that addition of
curdlan to the DTaP vaccine causes retention in the nasal cavity,
but without it, the vaccine components are more readily detected
in the lung.
To visualize the deposition of DTaP particles, sections from the
lung and nasal cavity were imaged using confocal microscopy.
Vaccinated mice were euthanized after 6 h, lung tissue was flash
frozen and skulls were embedded in paraffin for sectioning.
Sections from the lung and nasal cavity were counterstained with
NucBlue and ActinGreen to visualize epithelial tissue and
fluorescent DTaP particles (Fig. 2a, c). Vaccine particles were
quantified by measuring the percentage of total image field
emitting DTaP fluorescence. We detected a significant increase of
fluorescent particles in the lungs of mice that were vaccinated
with IN-aP compared to IN-caP (Fig. 2b). Using microscopy, there
was no significant difference in the number of particles detected
in the nares comparing IN-aP to IN-caP (Fig. 2d). Interestingly, we
observed that DTaP particles from the IN-aP vaccinated mice were
localized in the lumen of the nasal passages, while particles from
IN-caP vaccinated mice were deposited into the epithelial cells
(Fig. 2c). Overall these data suggest curdlan impacts localization of
DTaP in the airway.
Intranasal immunization induces production of anti-PT and anti-
FHA IgG in serum
To determine vaccine-induced protection, we utilized an estab-
lished vaccine and challenge protocol.42 CD-1 mice were
immunized IN with either IN-aP or IN-caP. These groups were
compared to pertussis immunizations that are known to be
protective: DTaP (IP-aP) and whole-cell pertussis (IP-wP) adminis-
tered intraperitoneally (IP). Additionally, we aimed to determine if
the effects of curdlan were dependent by route, thus we included
mice immunized with IP delivered DTaP and curdlan (IP-caP).
Lastly, we compared the findings to mock vaccinated mice, with
IN delivered PBS, or mice IN immunized with curdlan only (IN-
curdlan). All mice were immunized with 1/12th of the antigen load
contained in the human vaccine dose. Mice were vaccinated at
day 0, then received a booster vaccine at day 21. Mice were
challenged on day 35 with B. pertussis.
We first sought to determine if an IN delivered DTaP vaccine
would induce a systemic immune response. To answer this, we
performed enzyme-linked immunosorbent assays (ELISAs) with
serum from vaccinated and challenged mice against B. pertussis
antigens found in the vaccine: PT and filamentous hemagglutinin
(FHA). ELISAs were not performed against pertactin antigen, as
85% of current clinical isolates in the US do not express the
protein.43 Serum anti-PT IgG titers were similar between mice
immunized with IP-aP and those immunized through IN admin-
istration, as no significant differences were determined between
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IP-aP, IN-aP or IN-caP (Fig. 3a). Similarly, we observed a robust titer
response to the bacterial adhesin FHA in IN vaccinated mice;
however, IN-aP serum anti-FHA titer was sevenfold higher than IN-
caP (Fig. 3b). We next determined if IN administration of DTaP
(with or without curdlan) would lead to an increased Th1 immune
response resulting in a higher ratio of IgG2a compared to IgG1
antibodies. Neither route nor adjuvant impacted the ratio of IgG2a
to IgG1.
Intranasal immunization induces production of anti-B. pertussis IgA
in lung
In the murine model, recent data has pointed to the importance of
IgA and a local mucosal immune response in the lung and nasal
cavity.21,22,24,25 We aimed to measure the presence of IgA
antibodies in the murine respiratory tissue due to IN immuniza-
tion. Using ELISAs we measured B. pertussis specific IgA titers in
homogenized lung tissue supernatant and nasal lavage fluid.
Interestingly, we detected a robust IgA response in the lung only
when mice were immunized through the IN route (Fig. 4a).
Antigen-specific IgA response was not observed in mice
immunized with curdlan alone. We observed detectable IgA B.
pertussis-titers in the nasal lavage fluid from both IN-aP and IN-caP
vaccinated groups, although only IN-aP resulted in a significant
increase compared to baseline levels (Fig. 4b). The presence of B.
pertussis binding IgA in the lungs and nasal cavity suggests that IN
DTaP is capable of priming a mucosal immune response in the
upper and lower murine respiratory systems.
Intranasal immunization decreased pulmonary pro-inflammatory
environment
It has been well established that neutralization of PT and
inhibition of bacterial adhesins associated with DTaP protection
Fig. 1 Localization of acellular pertussis vaccine in the upper and lower respiratory system after IN vaccination. a Schematic of vaccine
tracking protocol. CD-1 mice were intranasally vaccinated with either fluorescent DTaP alone (IN-aP) or fluorescent DTaP with curdlan (IN-caP).
Vaccine particle deposition in the lungs and nasal cavity was measured at 0, 6, 12, 24, and 48 h after immunization. b Representative image of
Alexa Fluor labeled DTaP vaccine particles. c Representative images of nasal cavity fluorescence at 6, 12, and 24 h. The region of interest used
for fluorescence quantification is shown in blue. (d) Fluorescence measurements normalized to PBS control at 6, 12, and 24 h (n= 4). Results
shown as mean ± SEM of total radiant efficiency, *P < 0.05. P values were determined by multiple T-tests with Holm-Sidak post hoc test
between IN-aP and IN-caP vaccinated mice. e Representative plots at 12 h showing live, single cells that are CD11b+DTaP+. f Flow cytometric
analysis of CD11b+ cells from the lung that contain or are bound to DTaP particles at 6, 12, 24, and 48 h post immunization. Results shown as
mean ± SEM, *P < 0.05, ***P < 0.001, ****P < 0.0001 (n= 4). P values were determined by one-way ANOVA with Dunnett’s post hoc test
comparing IN-aP immunized mice to control mock vaccinated mice
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leads to a markedly reduced pro-inflammatory environment at the
site of infection when compared to a natural infection.17
Conversely, challenge in whole-cell protected animals resulted in
a severe pro-inflammatory response, similar to the natural
infection of B. pertussis.19 We hypothesized that the immunosti-
mulatory properties of curdlan would induce a more pro-
inflammatory response following challenge with B. pertussis
compared to IP-aP. Cytokine concentrations were determined
from supernatant of lung homogenate at day 3 pc. The pro-
inflammatory interleukin-6 (IL-6) has been shown to be increased
following B. pertussis infection of a naive mouse, while DTaP
induced protection drastically decreases IL-6 production.42,44 Our
results demonstrate a significant reduction of IL-6 in the lungs of
either IN-aP or IN-caP immunized mice when compared to mock
vaccinated or IN-curdlan control mice, and are comparable to
levels observed in IP immunized groups (Fig. 5a). We measured a
similar reduction in the Th1 associated cytokine IFN-γ in the IN
administered groups, IN-aP and IN-caP; although, these levels
were higher in IN-caP immunized mice (Fig. 5b). We only observed
a significant increase in the Th2 associated interleukin-5 in IN-wP
immunized mice compared to mock vaccinated mice (Fig. 5c)
IN administration of curdlan, and moreover, vaccine adminis-
tration through the IN route regardless of adjuvant has been
shown to induce an increased IL-17 response.30,32 Thus, we
hypothesized that we would observe increased levels of IL-17 in
mice immunized with IN-caP compared to IN-aP or IP-aP. We
quantified IL-17A in the lung supernatant and observed significant
increases of IL-17A with the addition of curdlan in IP-caP and IN-
caP immunized mice compared to IP-aP and IN-aP groups, 4-fold
and 14.9-fold respectively (Fig. 5d). Furthermore, we observed that
IN administration induced a significant increase in IL-17A
compared to IP immunization. This IL-17A response was lower
than the robust IL-17A induced by IP-wP (Fig. 5d).
Natural infection with B. pertussis is known to cause severe
leukocytosis in the murine model,45 which can be measured by
elevated neutrophils in the peripheral blood. Following B. pertussis
challenge, we observed that all vaccinated groups ameliorated
symptoms of leukocytosis by day 3 pc; however, only the
administration of DTaP either by IP or IN administration
significantly reduced CD11b+Gr-1hi neutrophils in the peripheral
blood (Fig. 6a). In the lungs, neutrophils were decreased in IN-aP,
IN-caP, and IP-aP immunized groups compared to mock
vaccinated mice.
Due to the expansion of TRM in the lungs observed by others
following administration of parenteral and intranasal administered
pertussis vaccines, we aimed to determine if IN-aP or IN-caP could
induce the expansion of this population. CD4 T cells were isolated
from the lung at day 3 pc, and were identified as TRM cells based
on expression of surface markers: CD4+ CD62L-CD44+ CD69+.
We did not observe a statistical difference of this population
following challenge with either IP or IN administered vaccines;
although, we did observe a slight increase in IP-wP, IP-caP, IN-aP,
and IN-caP compared to mock vaccinated mice (Fig. 6c). Taken
together these data suggest that immunization with DTaP
Fig. 2 Acellular pertussis vaccine particle localization altered by curdlan adjuvant. a Representative images of flash frozen lung sections 6 h
after immunization with IN-aP or IN-caP. Fluorescent particles were detected using a 660 laser, samples were counter-stained with NucBlue
(blue) and ActinGreen (green). b Fluorescent DTaP particles were quantified by determining the percentage area of particles per field of view.
(n= 3–4, with averages of three images per lung). Results are shown as mean ± SEM, *P < 0.05. c Representative images of paraffin embedded
nasal cavity sections 6 h after immunization with IN-aP or IN-caP. d Fluorescent DTaP particles quantified by determining the percentage area
of particles per field of view. (n= 3–4, with averages of three images per lung). P values were determined by one-way ANOVA with Tukey’s
post hoc test
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through the IN route reduces the pro-inflammatory environment
of the murine lung during B. pertussis challenge in a manner
similar to IP-aP-mediated protection.
Intranasal immunization reduced respiratory B. pertussis bacterial
burden
Lastly, we examined the clearance of B. pertussis from the
respiratory tract following IN immunization. At days 1 and 3 pc,
viable bacterial burden was quantified by counting of CFU in the
lung, trachea, and nasal lavage fluid. We observed a significant
reduction in viable bacteria recovered from the lung in all
immunized groups by day 3 pc; however, these changes were not
observed at day 1 pc (Fig. 7a, b). IN-aP and IN-caP immunized mice
bacterial burdens were reduced by 99.4% and 99.7%, respectively,
compared to mock vaccinated mice. This reduction in viable
bacterial burden was similar to that of mice immunized by IP-aP,
an immunization that is known to be effective (Fig. 7b). This
reduction in bacterial burden was not observed following
immunization with the negative control (IN-curdlan), suggesting
an antigen-specific response. Similar trends were observed in the
trachea homogenate (Fig. 7c, d), and nasal lavage fluid (Fig. 7e, f),
as all immunized groups regardless of IP or IN delivery were
significantly reduced compared to mock vaccinated mice. In
summary, we observed similar clearance of B. pertussis from the
respiratory tract of mice immunized IN compared to mice
immunized with vaccines known to be protection delivered by
the IP route.
DISCUSSION
The natural immune response to B. pertussis is initiated by the
colonization of the respiratory tract, which leads to a cascade of
inflammatory cytokines such as IL-6, IFN-γ, TNF-α, and IL-1β
leading to increased inflammatory infiltrate consisting of: dendritic
cells, macrophages, neutrophils, and lymphocytes.42,46 Numerous
studies suggest the infection is cleared through opsonization of
bacteria by the humoral immune response, combined with a Th1/
Th17 cell-mediated response.15,19,47,48 Additionally, factors asso-
ciated with a local immune responses have been observed in
convalescent mice following challenge with B. pertussis, such as
antigen-specific IgA titers and TRM cells, which were shown to
decrease bacterial burden when adoptively transferred to naive
mice.21
The induction of a protective immune response also has been
observed through mucosal immunizations against B. pertussis. Oral
vaccination with heat-killed B. pertussis in newborn infants
resulted in the production of B. pertussis specific serum and
mucosal antibodies; although, this protection was not long lived.49
In the mouse model, a live-attenuated IN pertussis vaccine, BPZE1,
has shown protection up to one year after immunization,50 and is
in clinical trials.51 Furthermore, BPZE1 vaccine produced antigen-
specific IgA antibodies in the baboon model, indicative of
elicitation of mucosal immune response.52 The mucosal immune
response was further explored in a murine model where BPZE1
induced a protective secretory IgA immune response, and the
generation of long lasting IL-17 secreting TRM cells in the
Fig. 3 Intranasal immunization induces production of anti-PT and anti-FHA IgG in serum. ELISAs were used to compare serological responses
from mice immunized through IN or IP routes to mock vaccinated mice. Total IgG serum antibody titers from immunized and challenged mice
were quantified against a PT and b FHA at day 3 pc. Serum c IgG1 and d IgG2 antibody titers against B. pertussis were compared to mock
vaccinated mice at day 3. Results shown as mean ± SEM, **P < 0.01, ***P < 0.001, ****P < 0.0001 (n= 3–8). P values were determined by one-
way ANOVA with Dunnett’s post hoc test compared to mock vaccinated mice
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respiratory system.24 Similarly, this population of antigen-specific
memory cells was found to be expanded by an acellular pertussis
vaccine (LP-GMP) consisting of a TLR2 agonist and intracellular
receptor STING agonist, which correlated with the IL-17 secreting
TRM population.
23 Promisingly, generation of the IL-17 secreting
TRM cell population was observed following whole-cell immuniza-
tion through IP administration; however, Tdap administration
through the same route did not generate this population.20
In our study, we demonstrate that by altering the administration
route of DTaP immunization from IP to IN delivery, the vaccine still
induced a protective immune response. Using fluorescent labeled
DTaP particles we visualized that IN-aP was readily detectable
(Fig. 1). In vivo imaging analysis demonstrated significantly more
labeled IN-caP present in the nasal cavity of mice. Further work
examining the lymph nodes responsible for antigen priming
would be beneficial to determine the role of nasal associated
lymphoid tissue compared to vaccination of the lung, and
trafficking to mediastinal lymph nodes. The location of antigen
priming following IN immunization may play a critical role in the
optimization of future human IN vaccines. Determining if antigen
uptake in the nasal cavity is essential to induce a protective
immune response would play a key role in the development of a
human IN pertussis vaccines.
We determined that while IN-caP vaccinated mice had
significantly lower detection of DTaP in the lungs compared to
IN-aP immunized mice that the bacterial burden was similar
between the two groups (Fig. 7), suggesting that antigen priming
still occurred. This was further demonstrated through generation
of robust antigen-specific serum IgG antibody titers from the two
IN immunized groups (Fig. 3). The IgG subclass data (Fig. 3)
suggest that immunization with IN-aP most likely induces a Th2
response. Other studies with BPZE1 or LP-GMP adjuvants have
observed shifts to Th1 response using IN route.20,24 Additionally, in
these studies the authors did not observe a significant reduction
in bacteria burden of the nasal cavity of mice parenterally
immunized with acellular pertussis. However, in the current study
we observed contradictory results suggesting significant reduc-
tions in nasal bacterial burden after IP-aP and IP-caP immuniza-
tions. The current study was performed using B. pertussis strain
UT25 with the challenge dose of 2 × 107 CFUs administered by
intranasal inoculation in 20 µl. The inoculum dose is higher than
previous mentioned studies, and those studies were also
performed using different B. pertussis strains and mouse strains.
Another difference that we believe is most likely accounting for
the discrepancies, could be the different methods of culturing
viable bacteria from the nasal cavity resulting in lower limits of
detection. The aforementioned studies and our study support the
idea that IN immunization can be protective, and further
development should be pursued.
A key finding of our current study was the production of
antigen-specific IgA in the respiratory system only in mice that
were administered DTaP through IN administration: IN-aP and IN-
caP (Fig. 4). Another difference between the IN-aP and IN-caP
groups was the level of IL-17A present in the lung homogenate
(Fig. 5). We found that inclusion of curdlan in DTaP resulted in
higher levels of IL-17A whether administered through IN or IP
route although IL-17A was highest in IN-caP. These findings
correlate with results from others suggesting a role of curdlan and
IN administration in IL-17 production.30,32 It is clear that other
formulations of intranasal pertussis immunizations are capable of
inducing a robust IL-17 response, specifically in the respiratory
tract, although in our current study the level of IL-17A production
in lungs was lower than other vaccine formulations.23,24 Likewise,
we did not observe an increase of TRM cells present in the lung
that has been demonstrated by the same groups.22–24 There is a
clear role of IL-17 secreting TRM cells in the immune response
against pertussis.21–23,25,53 It may be possible that the increases of
IL-17A observed in the lungs of IP-caP, IN-aP, IN-caP immunized
groups are related to the slight expansion of lung TRM cells;
however, further studies are needed to show that correlation. It is
known that live-attenuated vaccines are more potent inducers of
TRM populations.
54 Taking into account the pro-inflammatory
response to challenge following administration of wP, BPZE1 and
LP-GMP22–25 and the lack of inflammation observed following
challenge of mice immunized with IN-aP and IN-caP, it is
conceivable that IN-aP and IN-caP are not immunomodulatory
enough to induce a strong TRM response. This work demonstrates
induction of mucosal immune response specific to B. pertussis in
the respiratory system but, future work is needed to identify the
duration of protection.
In our model, addition of curdlan to DTaP increased IL-17
responses but did not improve clearance (Fig. 7). A caveat of the
current work is the role of aluminum hydroxide was not
addressed. All IN immunizations consisted of DTaP, which contains
aluminum hydroxide, therefore, observations from IN-caP may be
affected by the presence of two adjuvants. We hypothesized that
the addition of curdlan adjuvant into the DTaP formulation would
skew the immune response to a Th1/Th17 cell-mediated response.
The combination of multiple adjuvants paired to aluminum has
Fig. 4 Intranasal immunization induces production of anti-B.
pertussis IgA in respiratory system. ELISAs were performed using
a lung homogenate supernatant and b nasal lavage fluid from
vaccinated and challenged mice at day 3 pc. IgA titers were
determined against whole-cell B. pertussis. Results are shown as
averages of two independent experiments, represented on a
log10 scale for lung and linear scale of nasal lavage with mean ±
SEM (n= 4-8). ****P < 0.0001. P values were determined by one-
way ANOVA with Dunnett’s post hoc test compared to mock
vaccinated mice
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been explored previously, leading to the retention of antigens at
the injection site with the new benefit of recruiting APCs to the
site.55 The combination of MPLA with aluminum hydroxide has
been shown to increase antibody titers and shift the immune
response from Th2 to Th1 associated cytokine production from
spleen cells in vaccines for hepatitis B and human papilloma
virus.56 Likewise, the addition of CpG oligonucleotides with
aluminum hydroxide into a hepatitis B vaccine enhanced the
antibody response by shifting from IgG1 to IgG2a antibodies in
mice.57 In the case of these two vaccines aluminum hydroxide and
the adjuvants, MPLA and CpG induce protection through
mechanisms not shared by aluminum. As mentioned, curdlan as
a vaccine adjuvant is known to promote a Th1/Th17 skewed
responses.30,58 It has been demonstrated that curdlan binds to
dectin-1 inducing not only the canonical activation of NF-κB
subunits p65 and c-Rel, but also the non-canonical subunit RelB
through the spleen tyrosine kinase in human DC cells.59 Gringhuis
et al. measured NF-κB activation through Raf-1 kinase indepen-
dent of Syk following exposure to curdlan.31 Furthermore, the
authors demonstrate Raf-1 activation suppressed Syk-induced
RelB promoting the Th1/Th17 polarizing cytokines. Through this
mechanism, Raf-1 activation induced by curdlan modulated TLR-2
and TLR-4 induced cytokine expression.31 It may be possible that
dectin-1 cross-talk with other PRRs is interfering with aluminum
hydroxide-induced response. For instance, damage to phagolyso-
somes following the phagocytosis of aluminum has been shown
to activate the Syk signaling pathway, which is shared by dectin-1.
Additionally, both curdlan and aluminum hydroxide are known to
activate the NLRP3 inflammasome.60,61 Future studies will be
required to elucidate potential interference between adjuvants, as
these interactions may be limiting the immunomodulatory actions
necessary to induce the expansion of TRM and IL-17 response in
the respiratory tract. Future experimental vaccines with aluminum
hydroxide or curdlan will be compared with only one adjuvant in
Fig. 5 Intranasal immunization decreased pulmonary pro-inflammatory cytokines during challenge. Analysis of cytokines from supernatant of
lung homogenate at day 3 pc. Cytokines a IL-6, b IFN-γ, c IL-5, d IL-17A were quantified by electrochemiluminescence assay. Results shown as
mean ± SEM (n= 4–8), *P < 0.05, **P < 0.01, *** P < 0.001, ****P < 0.0001. P values were determined by one-way ANOVA with Dunnett’s post hoc
test compared to mock vaccinated mice. Bars connecting groups indicate values determined by two-tailed un-paired t-test. Upper and lower
limits of detection shown as dash or dotted lines, respectively if data points reached these limits
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each formulation. Alum is not used in any currently licensed nasal
vaccines and curdlan is not an approved adjuvant for use in
humans. Mucosal pertussis vaccines would require appropriate
safety evaluation to move forward for clinical development.
In conclusion, we observed that by altering the route of
administration from IP to IN a protective response was repro-
duced, resulting in clearance of the pathogen to limits of
detection. Furthermore, we determined that IN delivery of DTaP
was sufficient to prime a local mucosal immune response at site of
infection. The inclusion of the adjuvant curdlan in DTaP
immunization did increase IL-17 production in the lung; however,
we did not observe a shift in the type of immune response
compared to DTaP alone. In humans, DTaP and Tdap do not
provide perfect protection against pertussis; however, there is no
clear path forward to the next generation vaccine. It is clear that
developing a new vaccine will take considerable efforts. Here in
our study we observed a surprising result, that IN DTaP vaccine
could protect mice against B. pertussis. These data cause us to
wonder if a change in the route of DTaP immunization would be a
promising booster vaccine strategy.
METHODS
Composition and administration of vaccines used in study
The vaccines administered in the study were prepared no longer than 1 h
before administration. INFANRIX (GSK) human vaccine (DTaP), and the
National Institute for Biological Standards and Control WHO whole-cell
pertussis vaccine (NIBSC code 94/532) were used in the study. Vaccines
were diluted with PBS to 1/12th of the human dose (based on total antigen
content). Curdlan adjuvant was administered at 200 µg per mouse. A
vaccine dose of 1/12th the human dose was the highest concentration of
vaccine that was possible to use due to volume of vaccine required for the
solubility of curdlan. Curdlan (Invivogen, tlrl-curd) was prepared by
dissolving 50mg in 2.5 ml sterile purified water. Curdlan preparation was
brought into solution by adding 100 µl 1 N NaOH and vortexing. The
curdlan suspension (20 mg/ml) was then sonicated for 10min and placed
in 37 °C water bath until administration. At the time of immunization, the
vaccines containing curdlan were administered in a liquid form to reduce
risk of choking due to excessive gel formation in the airway. IN
administered mice recovered at the same rate of IP immunized mice.
These experiments were conducted in accordance with the National
Institutes of Health Guide for the care and use of laboratory animals. The
protocols used were approved by West Virginia University Institutional
Animal Care and Use Committees (WVU-ACUC protocol 1602000797).
Vaccination of mice for vaccine particle tracking
CD-1 (outbred; strain code 022) mice aged four weeks were obtained from
Charles River Laboratories. At five weeks mice were anesthetized with
77mg/kg ketamine and 7.7 mg/kg xylazine. Mice were administered 50 µl
of vaccine or control, with 25 µl into each nostril (IN).
Tracking of DTaP in respiratory system
DTaP vaccine particles were labeled using the Alexa Fluor 660 Protein
Labeling Kit (Molecular Probes). Briefly, 0.5 ml of DTaP vaccine was added
to 50 µl of 1 M sodium bicarbonate, then added to Alexa Fluor 660 dye
stock. The mixture was incubated for 1 h at room temperature with
agitation. The solution was concentrated by dialysis in phosphate-buffered
saline overnight to remove unlabeled dye. Vaccine particles were
examined using the Cy5 channel on an EVOS FL microscope. Particles
were mounted on a slide and visualized using a 100X objective. Particle
diameter was measured using ImageJ (version 1.52a) with the line
segment tool in proportion to the scale bar. Four fields of view were
measured to determine particle size and standard deviation. Labeled
vaccine was used to immunize mice. At 0, 6, 12, and 24 h post vaccination
fluorescent signal was measured using an IVIS Spectrum (Xenogen). Mice
were anesthetized using 3% isoflurane, mixed with oxygen prior to and
throughout imaging. The following parameters were used: (1) A binning
setting of 4 was kept constant for all images, (2) each image was quantified
using the automatic image setting, (3) fluorescence photons were
measured using total radiant efficiency of a common region of interest
placed on the nasal cavity, and (4) measurements were normalized using
Living Image (Xenogen ver. 2.5). Use of this quantification method
accounted for variations in exposure between images.
At 6, 12, 24, and 48 h post vaccination, animals were euthanized to
quantify DTaP in lungs by flow cytometry analysis. Lungs were removed,
and homogenized using gentleMACS C tubes (Miltenyi Biotec) with
enzymatic lung dissociation kit (Miltenyi Biotec, 130-095-927). All samples
were blocked using Fc Block (BD), then labeled with Alexa Fluor 700-
conjugated CD11b (Biolegend, 101222), DTaP particles were detected with
Cy5 channel. Following a 1 h dark incubation labeled samples were
washed, then fixed using 0.4% w/v paraformaldehyde overnight. Samples
were resuspended in PBS and analyzed on a LSR Fortessa flow cytometer
(BD). DTaP containing myeloid cells were classified as CD11b+DTaP+
single, live cells.
Detection of DTaP particles in lung and nasal cavity
Detection of DTaP particles in the lung and nasal cavity were confirmed
using confocal imaging. Mock vaccinated and challenged mice were
euthanized at 6 h post vaccination. Prior to homogenization, the post-caval
lobe of the mouse lung was removed. The post-caval lobe was flash frozen
in OCT medium (Tissue Plus, Fisher Healthcare), using liquid nitrogen. The
samples were stored at −80 °C until sectioning. Sectioned samples (6 µm)
were fixed in acetone, then stained with ActinGreen Ready Probes
Fig. 6 Intranasal immunization reduced neutrophil accumulation in the lung and circulating neutrophils, but did not generate lung TRM
population after B. pertussis challenge. a The percentage of live, CD11b+Gr-1hi neutrophils from a single cell suspension of the peripheral
blood. b The percentages CD11b+Gr-1hi neutrophils in single cell lung homogenates. c The percentage of CD4+ T cells that are
CD62L-CD44+CD69+ isolated from the lung at day 3 pc. Results shown as means ± SEM, *P < 0.05 **P < 0.01, ***P < 0.001, ****P < 0.0001 (n=
4–8). P values were determined by one-way ANOVA with Dunnett’s post hoc test compared to mock vaccinated mice
D.T. Boehm et al.
8
npj Vaccines (2019)    40 Published in partnership with the Sealy Center for Vaccine Development
(Invitrogen) and NucBlue Ready Probes (Invitrogen), using manufacturer
protocols.
Skulls were removed from mouse, and the lower jawbone discarded. The
skulls were fixed in formalin for 12 h at 4 °C, then de-calcified at room
temperature for 24 h, before samples were embedded in paraffin.
Sectioned samples were de-paraffinized and rehydrated using xylene,
and washes with decreasing ethanol concentrations (100–70%). An
antigen retrieval step was performed using citrate buffer, where samples
were heated to 98 °C for 20min. Samples were then stained as mentioned
above. Samples were analyzed for DTaP particles in tissue and airway
mucus using a Nikon A1R confocal microscope. Images were acquired
using DAPI, FITC, and Cy5 channels using a 100× oil immersion lens (100×/
1.40 Nikon Plan Apo). DTaP particles were quantified using ImageJ. Briefly,
the threshold tool was used to select only the fluorescent particles above
background levels. Then, the threshold adjusted area was quantified using
the analyze particles tool. Thus, the data is represented as the percentage
Fig. 7 Intranasal immunization reduced respiratory B. pertussis bacterial burden. Analysis of bacterial burden was determined at days 1 and
3 pc. Bacteria were quantified by counting of serially diluted CFUs following immunization and challenge. CFU counts were determined from
lung homogenate (a, b), trachea homogenate (c, d), and nasal lavage fluid (e, f). Results are mean ± SEM (n= 4–8, with four averaged technical
replicates) from two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. P values were determined by one-way ANOVA
with Tukey’s post hoc test compared to mock vaccinated mice, or between connected columns. The dashed line represents the lower limits of
detection due to plating
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of fluorescent particles per area of the total image field. Three image fields
per sample were quantified and averaged per mouse.
B. pertussis strains and growth conditions
B. pertussis strain UT25Sm162 was used for murine challenge in all
experiments. UT25Sm1 was cultured42 on Bordet Gengou agar plus 15%
defibrinated sheep’s blood (Remel) with streptomycin 100mg/ml. B.
pertussis was incubated at 36 °C for 48 h, then transferred to modified
Stainer-Scholte liquid medium,63 without the cyclodextrin, heptakis. Liquid
cultures were incubated for 24 h at 36 °C, with shaking until reaching an
OD600 of ~0.6, at which time cultures were diluted for challenge dose.
Vaccination and B. pertussis challenge
IN immunized mice received 50 µl of vaccine as described above. IP
immunized mice received 200 µl of vaccine injected into the peritoneal
cavity. IN and IP immunized mice received the same antigen dose of 1/
12th. Mice received a boost of the vaccines with the same concentrations
twenty-one days after initial immunization. At thirty-five days post initial
vaccination, mice were challenged with 2 × 107 CFU B. pertussis
administered in 20 µl through nostrils. At days 1 and 3 pc mice were
euthanized, blood and respiratory tissue were isolated as previously
described.42 Peripheral blood was collected by cardiac puncture following
euthanasia. Trachea and lungs were removed and separately homogenized
using Dounce homogenizers to determine viable bacteria burden in
respiratory tissue. A nasal cavity lavage was performed using 1mL of PBS
flushed through the nares to determine bacterial burden of nasal cavity.
Serial dilutions in PBS were plated on BG containing streptomycin (100 µg/
ml) to ensure that only UT25Sm1 B. pertussis was cultured
Serological analysis of B. pertussis specific antibodies
Serological responses specific to B. pertussis antigens were quantified by
ELISA. High-binding microtiter plates were coated with PT (50 ng/well)(LIST
Biologicals) and FHA (50 ng/well)(Enzo Life Sciences). Serological responses
against UT25Sm1 were cultured to an OD600 of 0.24 and microtiter plates
coated with 50 µl of bacteria per well. Bound antibodies were detected
using goat anti-mouse IgG (1030-04), IgA (1040-04), IgG2a (1081-04), and
IgG1 (1071-04) antibody conjugated to alkaline phosphatase (1:2000)
(Southern Biotech). Positive antibody titers were determined using a
baseline set at two times the average of blanks.
Quantification of pulmonary and blood APCs
To determine cell types infiltrating the lung and leukocytes present in
peripheral blood, single cell suspensions from the tissues mentioned
above were prepared, as described previously.42 Briefly, lung tissue was
homogenized by Dounce homogenizers, filtered with a 100 µm filter, and
red blood cells were lysed for 2 min at 37 °C (Pharmlyse). Single cell
populations were blocked by initial incubation with Fc Block (BD, 553141)
for 15min at 4 °C. Cell populations were incubated in the dark with
antibodies to cell surface markers for 1 h at 4 °C. Neutrophil populations
were identified using: PE-conjugated GR-1 (BD, 553128,1:500), Alexa Fluor
700-conjugated CD11b (Biolegend, 101222, 1:500). Neutrophils were
classified as CD11b+Gr-1hi single, live cells. TRM populations were
determined using: APC-Cy7-conjugated CD4 (Biolegend, 100526, 1:500),
BB515-conjugated CD44 (BD, 564587, 1:500), APC-conjugated CD62L (BD,
553152, 1:500), and BV421-conjugated CD69 (BD, 562920, 1:500). The TRM
gating strategy was adapted fromWilk et al., shown in Supplementary Fig. 1.21
Lung homogenate cytokine analysis
To quantify inflammatory cytokines at the site of infection, lung
homogenate samples were centrifuged at 19 × g for 4 min supernatant
was removed and stored at −80 °C. Quantitative analysis of cytokines was
performed using Meso Scale Discovery cytokine kits: V-PLEX pro-
inflammatory panel (K15048D) and IL-17A V-PLEX (K152RFD), per the
manufacturer’s instructions.
Statistical analysis
Experiments in the study were performed with 3 to 8 biological replicates.
Data were analyzed using GraphPad Prism 7. ROUT method was used to
removed outliers.64 Comparisons between groups were performed using
one-way analysis of variance (ANOVA) with Dunnett’s and Tukey’s post hoc
tests. Comparisons between groups with or without curdlan were analyzed
by two-tailed unpaired t-test, when applicable multiple T-tests with Holm-
Sidak post hoc test were applied to curdlan inclusion groups.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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